A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment
El-Khoueiry, Anthony B., Tchekmedyian, Nishan, Sanborn, Rachel E., Peguero, Julio Antonio, Pulver, Kerry, Dembla, Vikas, Thomas, Jacob Stephen, Chiang, Gary Gene, Densel, Mark, Sankar, Neil, Worland, Stephen Theodore, Gleich, Lyon L., Sikorski, Robert S.
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article